Study Summary
This trial is comparing the outcomes of starting treatment with venetoclax and obinutuzumab early versus starting treatment after symptoms appear, in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 7 Secondary · Reporting Duration: Up to 10 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Arm I (delayed V-O)
1 of 2
Arm II (early V-O)
1 of 2
Active Control
Experimental Treatment
247 Total Participants · 2 Treatment Groups
Primary Treatment: Venetoclax · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 22 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Tennessee | 100.0% |
How old are they?
18 - 65 | 100.0% |
What site did they apply to?
Regional Cancer Center at Indian Path Community Hospital | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 100.0% |
Frequently Asked Questions
For what purpose do doctors usually prescribe Venetoclax?
"Venetoclax is an effective treatment option for small lymphocytic lymphoma, [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) (cll), and lymphoid leukemia." - Anonymous Online Contributor
Are there other examples of Venetoclax's efficacy?
"In 2012, CHU de Dijon was the first to study venetoclax. Since then, there have been a total of 367 completed studies with 290 ongoing trials. The majority of these live studies are based in Seattle, Washington." - Anonymous Online Contributor
Where are these clinical trials taking place?
"In total, this clinical trial is being conducted in 103 locations, with the three main sites being Swedish Medical Center-First Hill in Seattle, Washington, Crossroads Cancer Center in Effingham, Ohio, and Columbus Oncology and Hematology Associates Inc in Columbus, Texas." - Anonymous Online Contributor
Are we still enrolling individuals in this test?
"Correct, the clinical trial is recruiting patients as of right now. The original posting was on December 14th, 2020, and the most recent update was on November 4th, 2022. They are looking for 247 patients total, which will be recruited from 100 different locations." - Anonymous Online Contributor
What is the latest on Venetoclax's FDA approval process?
"While Phase 3 trials have less data supporting efficacy than later stage trials, there is still some evidence, and multiple rounds of data support Venetoclax's safety, so it receives a score of 3." - Anonymous Online Contributor